Theriva Biologics Inc. reported cash and cash equivalents of $7.5 million as of September 30, 2025, compared to $11.6 million as of December 31, 2024. Following recent capital raises, cash increased to $15.5 million as of November 10, 2025, extending the cash runway into the first quarter of 2027. During the period, the company presented expanded Phase 2b clinical trial data for VCN-01 in metastatic pancreatic ductal adenocarcinoma at the European Society for Medical Oncology Annual Congress, and preclinical data for VCN-12 at the European Society of Gene & Cell Therapy Annual Congress. Theriva is preparing for regulatory discussions on a proposed Phase 3 study of VCN-01 in metastatic PDAC and a potential Phase 2/3 trial in retinoblastoma. Additional funding will be required to initiate new VCN-01 clinical trials.